Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

IS RT WAITING FOR FRUIT TO FALL OFF THE TREE???

Relief Therapeutics and AdVita Lifescience are set to enrol the first patient in a Phase II trial of an inhaled formulation of the former’s lead compound, RLF-100 (aviptadil), for preventing Covid-19-related acute respiratory distress syndrome (ARDS).

Relief Therapeutics and AdVita Lifescience are set to enrol the first patient in a Phase II trial of an inhaled formulation of the former’s lead compound, RLF-100 (aviptadil), for preventing Covid-19-related acute respiratory distress syndrome (ARDS).

A synthetic form of a vasoactive intestinal peptide, aviptadil is being developed by NeuroRx as Zyesami in partnership with Relief Therapeutics.

Named ‘Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS’, the randomised, double-blind, placebo-controlled trial will be carried out at various clinical sites in Switzerland.

https://www.clinicaltrialsarena.com/news/relief-advita-ards-prevention/